Ceftriaxone Sodium is a third generation cephalosporin belonging to beta lactam group of antibiotics. It is a broad spectrum bactericidal parenteral cephalosporin. The bactericidal action of Ceftriaxone is believed to be due to inhibition of cell wall synthesis leading to lysis of the bacterial cell. Tazobactam Sodium, a triazolylmethyl penicillanic acid sulfone, is a new beta lactamase inhibitor with a range of activity that includes extended spectrum plasmid mediated beta lactamases. Tazobactam lacks significant antibacterial activity of its own. By rendering ß– lactamase inactive, tazobactam is able to protect the activity of various ß–lactam antibiotics. Tazobactam does not appear to have ß–lactamase inducing properties.
Ceftriaxone 1000 mg + Tazobactam
Ceftriaxone Sodium is a third generation cephalosporin belonging to beta lactam group of antibiotics. It is a broad spectrum bactericidal parenteral cephalosporin. The bactericidal action of Ceftriaxone is believed to be due to inhibition of cell wall synthesis leading to lysis of the bacterial cell. Tazobactam Sodium, a triazolylmethyl penicillanic acid sulfone, is a new beta lactamase inhibitor with a range of activity that includes extended spectrum plasmid mediated beta lactamases. Tazobactam lacks significant antibacterial activity of its own. By rendering ß– lactamase inactive, tazobactam is able to protect the activity of various ß–lactam antibiotics. Tazobactam does not appear to have ß–lactamase inducing properties.
Ceftriaxone & Tazobactam is used for treatment
• Respiratory tract infection, Urinary tract infection
• Skin and soft tissue infection, Bacterial Septicaemia
• Bacterial Meningitis, Surgical Prophylaxis
• Acute bacterial otitis media, Pelvic inflammatory disease
• Uncomplicated gonorrhea, Intra-abdominal infections
The combination of tazobactam and ceftriaxone is active against all the organisms sensitive to ceftriaxone. In addition, it demonstrates synergistic activity (reduction in minimal inhibitory concentrations [MICs] for the combination versus those of each component) in a variety of organisms.
Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam: About 30% bound to plasma proteins; widely distributed to tissues and body fluids.
Ceftriaxone: Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug.
Common adverse drug reactions (ADRs) for the ß-lactam antibiotics include
• Diarrhea
• Nausea
• Rash
• Urticaria
Before taking this medicine, tell the doctor about any medical problems and allergies that the patient has now or has had in the past.
Combination is contraindicated in patients with known allergy to pencillin or any other ingredients of the formulation.
From the above discussion, it can be concluded that this Ceftriaxone with Tazobactum improve the quality of life and help to cure Respiratory tract infection, Urinary tract infection, Skin and soft tissue infection, Bone and joint infection, Bacterial Septicaemia, Bacterial Meningitis, Surgical Prophylaxis.
Plot No.: 177, Industrial Area,Phase-II, Chandigarh(U.T.)-160002
+91 9216161607 levanzapharma@gmail.com
© 2017 levanzapharma.com, All Rights Reserved